Elise C. Kohn, M.D.
Medical Oncology Branch and Affiliates
Head, Molecular Signaling Section
Senior Investigator
National Cancer Institute
9000 Rockville Pike
Building 10, Room 12N226, MSC 1906
Bethesda, MD 20892
Phone: 301-402-2726
Fax: 301-480-5142
kohne@mail.nih.gov
Dr. Kohn is a graduate of the University of Michigan Medical School where she also completed residency training in internal medicine; she came to NCI for medical oncology training in the Medicine Branch. Dr. Kohn then joined the Laboratory of Pathology to investigate signal transduction molecular targets in invasion, angiogenesis, and ovarian cancer, and maintained her clinical focus in the translational clinical studies of ovarian cancer. Recently, Dr. Kohn has been involved in the identification and characterization of two proteins involved in ovarian cancer and cellular stress. In parallel, her clinical work has evolved to include the newest proteomic technologies applied to early detection testing and validation of therapeutic targets in clinical trials. Dr. Kohn also applies the advanced proteomic applications to her laboratory studies of stress pathways, growth factor regulation, and angiogenesis.
Dr. Kohn serves on numerous NIH and NCI committees, and is the newly elected chair of the Integration Panel of the Department of Defense Ovarian Cancer Research Program. Dr. Kohn is a participating member and protocol investigator in the Gynecologic Oncology Group, is a judge of the yearly Fellows Award for Research Excellence competition, and is the co-chair of the Breast and Gynecologic Malignancies Faculty. She was recognized with the NCI Diversity Award and Mentor of Merit Award in 2007. Dr. Kohn was elected as a Fellow of the American Association for the Advancement of Science.
Dr. Kohn's Clinical Trial(s):
NCI's Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with breast, fallopian, ovarian, peritoneal cancers, or solid tumors. Click on the trial(s) below for additional details, including a summary of eligibility criteria, study outline, and information on how to contact the study team directly.
Back to Top
